Antidepressants a brother "easy owner!" 9 billion market 6 over 500 million brands bright eyes

According to the WHO, there are more than 300 million people living with depression worldwideThe prevalence rate of depression in China is 2.1%, depression has become a global concern, but also promote the expansion of the market for antidepressantsAccording to Minet.com, sales of antidepressants at the end of Public Medical Institutions in China exceeded 9 billion yuan in 2019, up more than 10% year-on-yearIn recent years, with the continued efforts of domestic pharmaceutical companies such as Jingwei Pharmaceuticals, Huahai Pharmaceuticals, Kanghong Pharmaceuticals, Collon Pharmaceuticals and Haussen Pharmaceuticals, the market share growth rate of foreign pharmaceutical companies has slowed, and even some of them have declinedBrands TOP20, there are six brands more than 500 million yuan, of which, Lingbei oxalic acid Aesexi plantablet tablet sales fell by more than 20%, down nearly 200 million yuan, from the first place in 2018 to third, while Pfizer's hydrochloric acid sequoia, Yamatokyo Wei Pharma's oxalic acid Aescita planop stakes first and second placethe recent sales of anti-depressive drugs in public medical institutions in China (units: 10,000 yuan)the Healthy China Initiative (2019-2030) released last July, proposed 15 major special actions to promote mental health, and further refined the targets, including by 2022 and 2030, the current rate of insomnia, anxiety disorders, depression prevalence increased on the basis of 30 percent and 80 percentIn addition, it is proposed to integrate social resources and set up mental health counseling centers for minors at the municipal and county levelsIn recent years, china's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) terminal antidepressant market has grown rapidly, with sales exceeding 9 billion yuan in 2019, according to Minet.comin recent years, China's public medical institutions terminal antidepressant channel pattern
from the channel pattern, in recent years, urban public hospitals gradually decline, in 2019 market share fell below 80%;2019 China's urban public medical institutions terminal antidepressant enterprise competition pattern
from the enterprise competition pattern, Pfizer, Lingbei, Lilly three foreign pharmaceutical companies in the top three positions, 2019 market share is more than 10%, Pfizer is the firstIn recent years, with the continued efforts of domestic pharmaceutical companies such as Jingwei Pharmaceuticals, Huahai Pharmaceuticals, Kanghong Pharmaceuticals, Collon Pharmaceuticals and Haussen Pharmaceuticals, the market share growth rate of foreign pharmaceutical companies has slowed, and even some of them have declinedChina's public medical institutions terminal antidepressant brand TOP20 (units: 10,000 yuan)brand TOP10, Pfizer, Lingbei, Lilly and other foreign pharmaceutical companies occupy 4 seats; In terms of sales, six brands exceeded 500 million yuan, of which lingbei oxalic acid Aisiplana tablet sales fell the most, down nearly 200 million yuan year-on-year, from the first to third place in 2018, while Pfizer's hydrochloric acid schaeuble, Yamatokyo Wei Pharma's oxachloric acid Acesieplanaplan tablets took first and second placein recent years, China's public medical institutions terminal Aisisiplan tablet sales (units: 10,000 yuan) oxalic acid Essipril tablets by H Lundbeck A/S and Allergan joint development, mainly used to treat depression, in August 2002 the drug was approved by the FDA for sale The U.S oxalic acid Aescita plan tablet manufacturers are mainly Lupin, Torrent, Cipla, etc., the product was approved for listing in China in 2006 According to the data of Minnet According to the data, in 2019 the sales of aixiplan tablets at the end of Public Medical Institutions in China are nearly 2 billion yuan, and the main production enterprises are Yamasto Wei Pharmaceuticals, Lingbei, Sichuan Collum Pharmaceuticals, Hunan Dongting Pharmaceuticals, Jinhua Kangenbei Biopharmaceuticals, Jilin West Point Pharmaceuticals In November 2019, Zhejiang Huahai Pharmaceuticals' oxalic acid Aisi sipriate tablets were approved for listing in imitation 4 categories, as if approved by consistency evaluation it's worth mentioning that in 2018, Lingbei's oxalic acid Aceciplan tablets dominated the brand of antidepressants with a growth rate of more than 30%, with a market share of up to 45.68 percent, and sales declined significantly in 2019, with a market share of only 35.27 percent In addition, sales of Oxalic Aisi-Si-Panplan tablets from Tokyo-Tokyo Wei Pharmaceuticals exceeded 700 million yuan in 2019, while sales of Sichuan Collum Pharmaceuticals, Hunan Dongting Pharmaceuticals and Jinhua Kangenbei Biopharmaceuticals grew by more than 30% in recent years, China's public medical institutions terminal Agomeratin tablet sales (units: 10,000 yuan) agomelatin for adult depression treatment, by the French Schviahara original research Howson Pharmaceuticals' Agomeratin tablets (commodity name: Amenin) are the first generic drug of China's Agomeratin, which went on sale in 2014 and is the only agomylatin generic drug approved for sale in the country According to Minet.com, a number of end-of-market sales of Agometin tablets in China's public medical facilities grew rapidly, exceeding 200 million yuan in 2019, up 98.24% year-on-year, with strong growth to "kill" the top 10 antidepressant brands data show that in September last year, Sanofi China and Schvia China reached an exclusive strategic cooperation agreement on the antidepressant Agomeratin (product name: dimension new) developed by Sweetta, and Sanofi China will be fully responsible for the marketing and promotion of the drug after it goes on sale In April, According to Sanofi China, Dimension new prescriptions were issued simultaneously in Beijing and Xi'an antidepressant review as of June 15, antidepressants have 10 products through (including the adoption of the same pass) consistency evaluation, of which, hydrochloric acid vesidine slow release tablets, hydrochloric acid loxistinintestinal capsules, hydrobromic acid ciitalopran capsules and other 5 products only 1 enterprise sat, and oxalic acid Aesexi plan tablets rated the largest enterprises, involving Tokyo Wei Pharmaceutical, Sichuan Pharmaceuticals, Zhejiang Pharmaceuticals, etc original title: "Antidepressant one brother" changed owner! Howson, Collum, Huahai..." Hit the 9 billion market, 6 super 500 million brands bright eyes